Who is sponsoring NCT03800433?

NCT03800433 is sponsored by Ain Shams University.

What condition does NCT03800433 study?

NCT03800433 studies Anemia Renal.

What drugs are being tested in NCT03800433?

Interventions: Trental 400 MG Extended Release Oral Tablet.

What is the status of NCT03800433?

NCT03800433 is currently UNKNOWN.

Last reviewed 2019-09-24 · How we verify

Impact of Pentoxifylline Administration on the Modulation of Hyporesponsiveness to Erythropoietin Stimulating Agents in Hemodialysis Patients

NCT03800433 EARLY_PHASE1 UNKNOWN

The aim of the study is to assess the impact of pentoxifylline administration on the modulation of hyporesponsiveness to erythropoietin stimulating agents in hemodialysis patients

Details

Lead sponsor	Ain Shams University
Phase	EARLY_PHASE1
Status	UNKNOWN
Enrolment	46
Start date	2019-10
Completion	2020-04

Conditions

Anemia Renal

Interventions

Trental 400 MG Extended Release Oral Tablet

Primary outcomes

The difference in hemoglobin and hematocrit concentration between the intervention and control groups at the end of the study — up to 6 months post baseline
Patients will be evaluated regularly every month for hemoglobin concentration
safety & tolerability of pentoxifylline ( frequency of adverse drug effects due to Pentoxifylline as well as compliance with pentoxifylline). — up to 6 months post baseline
Patients will be evaluated regularly for frequency of adverse drug effects due to Pentoxifylline as well as compliance with pentoxifylline